drugset / Trial / NCT03129490
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
RandomizedCrossoverSingle-blindPrevention
Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in atrial fibrillation and atrial flutter across Danish hospitals and cardiology clinics.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2027-10-30
- Completion
- 2027-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apixaban | Small molecule | — | Oral |
| Comparator | Dabigatran etexilate | Unknown | — | Oral |
| Comparator | Edoxaban | Small molecule | — | Oral |
| Comparator | Rivaroxaban | Other / unclassified | — | Oral |